Question

Problem 16-5 Amy Dyken, controller at Flint Pharmaceutical Industries, a public company, is currently preparing the calculati(a) Basic earnings per share. Basic earnings per share (b) Diluted earnings per share. Diluted earnings per share Click if yo

0 0
Add a comment Improve this question Transcribed image text
Answer #1
Please hit LIKE button if this helped. For any further explanation, please put your query in comment, will get back to you.
Part a
Net Income $       1,480,000
Less: Preferred Dividend ($1,287,500*6%) $           (77,250)
Net income available for equity stockholder a $       1,402,750
No of common stock b               980,000
a/b $               1.431
Part b
Net Income $       1,480,000
Less: Preferred Dividend ($1,287,500*6%) $           (77,250)
Add: Bond Interest, Net of tax
Bond interest ($4,920,000*9%) $       442,800
Less: tax 40% $     (177,120) $           265,680
Net income for Diluted EPS a $       1,668,430
No of Common Stock               980,000
Add: Potential shares for Convertible Bonds               246,000
$4,920,000/$1,000*50 Shares
Add: Potential shares for Options (210,000-168,000)                 42,000
Options granted for           210,000
*Exercise Price $                  16
$   3,360,000
Divided By: average price $                  20
$       168,000
No of shares for Duluted EPS b           1,268,000
Diluted EPS a/b $                  1.32
Add a comment
Know the answer?
Add Answer to:
Problem 16-5 Amy Dyken, controller at Flint Pharmaceutical Industries, a public company, is currently preparing the cal...
Your Answer:

Post as a guest

Your Name:

What's your source?

Earn Coins

Coins can be redeemed for fabulous gifts.

Not the answer you're looking for? Ask your own homework help question. Our experts will answer your question WITHIN MINUTES for Free.
Similar Homework Help Questions
  • Amy Dyken, controller at Pina Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Pina Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Pina’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. PINA PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,950,000 Total long-term debt $12,000,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...

  • (Show work and calculations) Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently...

    (Show work and calculations) Amy Dyken, controller at Blue Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blue’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2017. BLUE PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt    Notes payable, 9% $980,000    8% convertible bonds payable 4,960,000    9% bonds payable 5,940,000      Total long-term debt $11,880,000 Shareholders’ equity    Preferred stock,...

  • Amy Dyken, controller at Metlock Pharmaceutical Industries, a public company, is currently preparing the calculation fo...

    Amy Dyken, controller at Metlock Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Metlock's financial statements. Below is selected financial information for the fiscal year ended June 30, 2017 METLOCK PHARMACEUTICAL INDUSTRIES SELECTED BALANCE SHEET INFORMATION JUNE 30, 2017 Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable $1,020,000 5,080,000 6,110,000 $12,210,000 Total long-term debt Shareholders' equity Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,010,000    9% convertible bonds payable 5,030,000    10% bonds payable 5,990,000      Total long-term debt $12,030,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for...

    Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan financial statements Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term diebt Notes payable, 10% 9X convertible bonds payable 10% bonds payable Total long-term debt $1.000.000 5,050,000 5.920,000 $11.970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...

  • Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the...

    Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Monty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Monty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% 8% convertible bonds payable 11% bonds payable Total long-term debt $980,000 5,030,000 6,100,000 $12,110,000 Shareholders' equity Preferred stock, 6% cumulative,...

  • Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Oriole Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Oriole’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Oriole Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 9% $980,000    8% convertible bonds payable 4,960,000    9% bonds payable 5,940,000      Total long-term debt $11,880,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 10% $1,020,000    8% convertible bonds payable 5,080,000    10% bonds payable 6,110,000      Total long-term debt $12,210,000 Shareholders’ equity    Preferred stock, 6% cumulative, $50 par...

  • Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...

  • Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for...

    Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt    Notes payable, 11% $1,020,000    9% convertible bonds payable 5,020,000    11% bonds payable 6,120,000      Total long-term debt $12,160,000 Shareholders’ equity    Preferred stock, 5% cumulative, $50 par...

ADVERTISEMENT
Free Homework Help App
Download From Google Play
Scan Your Homework
to Get Instant Free Answers
Need Online Homework Help?
Ask a Question
Get Answers For Free
Most questions answered within 3 hours.
ADVERTISEMENT
ADVERTISEMENT
ADVERTISEMENT